

Mutation scanning using high-resolution melting

Claire F. Taylor¹

Cancer Research UK Genome Variation Service, St James's University Hospital, Leeds LS9 7TF, U.K.

Abstract

Mutation scanning techniques are used to detect sequence variants without the need for prior knowledge of the identity or precise location of the variant, in contrast with genotyping techniques, which determine the status of a specific variant. High-resolution melting is a recently developed method that shows great potential as a mutation scanning technique. Sensitivity and specificity for mutation detection are extremely high and the technique also has advantages of cost and throughput. Practical considerations for successful mutation scanning by high-resolution melting are also discussed in this review.

Principle of HRM (high-resolution melting)

HRM is a simple, PCR-based method for detecting DNA sequence variation by measuring changes in the melting of a DNA duplex. Melting of double-stranded DNA molecules is influenced by several factors. Some of these, such as the length, GC content and sequence, are properties of the individual molecule [1]. Others are not: these include the ionic strength of the buffer solution, the DNA concentration and the presence of substances such as DMSO or betaine [2,3]. For HRM analysis, duplexes may be formed from the two strands of a PCR amplicon [4–6] or from an oligonucleotide probe and an amplicon strand [7–9]. Amplicon melting has been used for both genotyping and mutation scanning [5,6]. Probe melting is restricted to detecting variation within the probe-binding site. It has generally been used for genotyping applications [10], although there is scope for limited scanning because the presence of variants under the probe other than the target variant also perturbs probe melting [7].

A homozygous sequence variant usually changes the T_m of the duplex. Where there is an exchange between G:C and T:A base pairs, the change in T_m is relatively large: approx. 0.8–1.4°C [6]. If, however, the bases swap strands but the base-pair does not change, the change in T_m is smaller, becoming undetectable if there is also nearest-neighbour symmetry [6]. A heterozygous sample contains four duplex species (Figure 1A) and its observed melting curve is a composite of the four individual melting curves. The contribution from the relatively unstable heteroduplexes changes the shape of the heterozygous melting curve (Figure 1B) [5,6].

Duplex melting is generally monitored using intercalating dyes, although fluorescently labelled primers have also been used [4]. These dyes, which bind to double-stranded but not single-stranded DNA, fluoresce when bound but not after release on duplex melting. Dyes such as LCGreen, able to saturate available binding sites at a concentration compatible with PCR, are necessary for successful HRM. As a consequence of

dye redistribution during melting, non-saturating dyes, such as SYBR Green, are biased against low-temperature melting species and do not detect heteroduplexes [5,11].

HRM is a simple method: after PCR, carried out in the presence of a suitable dye, the product is heated while the level of fluorescence is measured. As the temperature rises and the duplex passes through its melting transition, dye is released and fluorescence intensity is reduced. Although several instruments capable of performing the fluorescence acquisition exist, they vary in performance, with those designed for HRM giving a more satisfactory outcome [6,11–14].

Low-resolution melting data and HRM data in a genotyping context are often viewed as a derivative plot ($-dF/dT$ against T), whereas for mutation scanning, a different approach to data analysis is taken [4]. A group of raw melting curves show variation in both the fluorescence and temperature axes (Figure 2A). Normalization of fluorescence before and after the melting transition (Figure 2B) corrects fluorescence variation caused by factors such as variable amplicon levels. Temperature variation poses more of a problem: variations in the observed T_m are caused not only by sequence-dependent T_m changes but also, for example, by buffer differences between samples and by non-uniformity across microtitre-format melting instruments [15]. These extrinsic variations are of similar magnitude to sequence-dependent changes in T_m [6,15]. Normalization of temperature, known as temperature shifting (Figure 2C), is a necessary correction for these variations, but at the expense of homozygote detection [5]. Finally, the melting curves are often converted into a subtractive difference plot (Figure 2D) in which the sample melting curves are shown relative to a wild-type control curve. Difference plots are more informative than derivative plots [4,5], and can make even subtle changes in the shape of the melting curve readily apparent [10,14].

HRM in practice: evaluation and application

Although amplicon HRM has been used as a genotyping technique [4,5,16], it is as a scanning technique that it finds wider application [10,17–42]. Together, these studies have examined


Key words: amplicon, genotyping, high-resolution melting (HRM), mutation detection, mutation scanning, sequence variant.

Abbreviations used: HRM, high-resolution melting.

¹email taylor_claire_f@yahoo.com

Figure 1 | Homoduplexes, heteroduplexes and their melting curves

(A) The four duplexes formed after PCR from a heterozygous sample: two fully matched homoduplexes, one wild-type and one mutant, and two mismatched heteroduplexes, formed from the pairing of a mutant strand with a wild-type strand. (B) Schematic melting curves from wild-type, homozygous and heterozygous samples. The homozygous curve has a different T_m from the wild-type curve, whereas the heterozygote curve has a different shape from the wild-type.



hundreds of mutations in many different genes. Human genetic disease has been the largest area of application, with investigations into autosomal dominant, recessive and X-linked disorders. The other main application has been the identification of somatic mutations acquired by human tumours.

The sensitivity of heterozygote detection has been remarkable, with many of the studies able to detect all heterozygous mutations examined [16–19,21,23–25,27,30,31,33,34,41,42]. Even where false negative results have been reported, they represent a small proportion of the total, suggesting that the true sensitivity indeed approaches 100%. All categories of substitution are detectable, as are insertions and deletions small enough to be amplified by PCR. Mutations are detectable at any location in the amplicon, including those within a few base pairs of the primers [19,27].

In principle, temperature shifting during data analysis renders homo- or hemi-zygous mutations undetectable, but in practice many homozygous mutations are detected [23,25,27,36,41,42], suggesting that the shape of the melting curve is in fact sometimes changed in homozygotes [5]. Hemi- or homo-zygous mutations are most likely to be encountered when screening genes mutated in X-linked conditions and in recessive conditions where common or founder mutations are frequent. Pre-PCR mixing of such samples with wild-type template [19,20,27,35,36] can avoid this problem, as can extending screening to obligate heterozygote carriers [41]. Internal temperature calibration

using 3'-blocked double-stranded oligonucleotides increases the discrimination of homozygous mutations from wild-type in short amplicons [15,43] and may also prove to be applicable in a scanning context. Screening for sequence variation in haploid organisms on the basis of changes in T_m rather than melting curve shape has been described in [44,45].

Greater amplicon length and lower GC content may have an association with false negative results, but the relationship does not seem to be straightforward [42,46]. Location of the variant within the fragment can clearly affect the magnitude of the change to the melting curve for an individual variant [46], but again, there appears to be no simple relationship between location and sensitivity. Adjustment of PCR primers [22] or analysis parameters [23,26] allowed detection of some variants initially scored as false negative. Others were caused by clerical errors [10] or were associated with sample source and preparation [26,28] and a few remained unaccounted for [20].

In tumour specimens, or in constitutive DNA from individuals mosaic for a germline mutation, the proportion of mutant DNA may deviate considerably from the 50% usually present in a heterozygote. Several studies have quantified the minimum level of mutant DNA detectable by HRM [22,26,29,30,42]. The lower limits defined are rather variable: some of this variation appears to be mutation specific [29,30] and there may also be an association with amplicon length [42]. A minority of mutations may have a lower detection limit in the range of 10–25%; many are detectable at 5% or lower. Clearly, HRM is more sensitive to low-level mutations than DNA sequencing [26,32,42]. Nevertheless, several false negative results were found when screening tumour samples for somatic mutations [26,29,32,38]. It seems that, in many cases, the proportion of mutant DNA in the sample fell below the detection threshold: either the same variant was clearly detected in other samples containing a larger proportion of tumour cells [29,32] or became detectable on re-preparation of the sample to contain a greater proportion of tumour [38].


Specificity, the proportion of true negatives correctly identified as such, is an important parameter, especially with high-throughput applications, because every false positive result generates unnecessary downstream sequencing. Accurate determination of specificity requires analysis of large numbers of known wild-type samples. Several studies have estimated the specificity of HRM, with most finding that it is in the range of 90–100% [16,22–24,26,28,33–35,38,46]. Specificity may be higher in shorter amplicons [46] and seems to have been adversely affected by sample quality in some [24,42] but not all [28] cases.

HRM: considerations for experimental design

Effective amplicon design is an important consideration for successful HRM. Robust and well-optimized PCR is needed for maximum sensitivity and specificity [23,35], and melting behaviour of the amplicon has an impact on the results [22,41]. The number of melting domains in an amplicon is determined

Figure 2 | Processing of HRM mutation screening data

(A) Raw melting data. The pre- and post-melting regions of the curve selected for fluorescence normalization are indicated by curly brackets. (B) Fluorescence-normalized melting data. The region of the curve selected for temperature normalization (temperature shifting) is indicated with an arrow. (C) Temperature-shifted, fluorescence-normalized melting data. (D) Subtractive difference plot.



by the distribution of G:C base-pairs. While the requirement to cover the entire region of interest, usually coding exons and splice sites, is paramount, various ways of manipulating primer design and location to improve the melting characteristics of the amplicon have been devised. Algorithms that predict melting behaviour from sequence have been used to optimize primer location [17,22,24,27,31,41]. Amplicon melting has been modified by using GC-clamped primers [41] or mismatched primers of reduced GC content [22]. HRM has been successfully performed in amplicons of 38–1000 bp [6,46], but most studies have used fragment sizes in the range of approx. 100–300 bp. T_m changes are greater in smaller amplicons [4] and evidence also suggests that the magnitude of the change to a heterozygote melting curve, and hence the heterozygote detection-sensitivity, are also greater in smaller amplicons [4,42,43,47]. In one study, a control mutation, missed when located in an amplicon with a complex melt profile, could be seen easily when the primers were redesigned to amplify two shorter overlapping fragments [22]. Nested PCR has been successfully applied, for example, where genomic complexity necessitates long-range PCR to mediate specific amplification of the sequence of

interest without co-amplification of homologous sequences [47].

Samples from many sources are suitable for HRM. Many of the applications have been in human genetic disease, and DNA extracted from peripheral blood lymphocytes is a widely used source. It has been noted that when samples prepared in different laboratories or by different extraction methods are run alongside one another they can produce visibly different melting curves [15,23]. Whole genome amplification methods have been used in conjunction with HRM [18,26,33], although one study found a reduction in sensitivity in whole-genome-amplified material [26]. Other sample sources have included dried blood spots [36], buccal cells [33] and frozen tumour specimens [22,26,48]. Archived samples in the form of methanol-fixed tissue [28], formalin-fixed paraffin-embedded tissue [24,26,28,34,38,40] and cytology slides [28,29,39] have also been analysed successfully, although, again, sensitivity may be reduced [26,28]. Although the amount of template has been quantified before PCR in most studies, there may be reasonable tolerance of variation in quantity provided that samples amplify well [24,33].

Where multiple samples contain the same variant, the mutant melting profiles group together tightly [10,17,27,31,37], whereas, in many cases, different variants in the same amplicon [14,17,20,21,26,37] or compound heterozygotes [14,36] produce distinct profiles. However, as it has been shown that different variants can give rise to indistinguishable profiles [10,18,23,33], it would be unwise to assume that the shape of the melting curve is diagnostic of the underlying variant, and specific confirmation of the causative variant is prudent. PCR products are not consumed by HRM, so positive samples can be transferred directly to sequencing for mutation identification and confirmation [27,35].

The presence of a high-frequency benign polymorphism within an amplicon can be challenging for HRM, as for other scanning techniques, because polymorphisms are detected as effectively as disease-causing mutations. Consequently, in the presence of a common polymorphism, the positive predictive value of a variant profile can be low [10] and the need to confirm the identity of variants means that excess sequencing has to be carried out [24,27,34,35,38,39]. Simple avoidance is not always possible, particularly for polymorphisms close to or within exons. PCR using primers containing a mismatch to both alleles of the polymorphism has been described [24]. Combined probe and amplicon melting of asymmetric PCR products is a further option [9,10,49]. Other solutions make use of the observation that biological replicates have reproducible melting profiles. A 1:1 mix of a test sample believed to be heterozygous for a specific variant with a confirmed heterozygous control will produce a melting profile identical with the two unmixed samples if both contain the same variant but not if they contain different variants [47]. More recently, a redundant screening strategy has been devised [35,36]. In addition to HRM screening of exons, short-amplicon genotyping HRM assays are performed. The results of exon scanning are compared with the genotyping result. If concordant, the genotype is assigned without the need for sequencing. If the results are inconsistent or if the exon melting profile does not group with the polymorphism control, then the sample is sequenced.

Concluding comments

HRM has been shown to have high sensitivity and specificity, with a performance as good as, if not better than, other commonly used mutation scanning techniques [50]. There are other attractions: only a single analysis condition is used and it is not necessary to tailor this to the individual amplicon, in contrast with many other widely used methods [31,50]. HRM is a closed tube system, which not only reduces the potential for contamination, but also increases sample throughput because there is no requirement for physical separation of DNA molecules [50]. HRM offers significant savings in cost and turnaround time [16,19,37,40,47] when compared with other scanning methods. Ease of use, high sensitivity and specificity, low cost and rapid turnaround make HRM an attractive choice for mutation scanning, especially in high-throughput environments.

Acknowledgements

I am grateful to Mike Churchman and Phil Chambers for helpful comments on the manuscript.

References

- Ririe, K., Rasmussen, R. and Wittwer, C. (1997) Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. *Anal. Biochem.* **245**, 154–160
- Rees, W., Yager, T., Korte, J. and von Hippel, P. (1993) Betaine can eliminate the base pair composition dependence of DNA melting. *Biochemistry* **32**, 137–144
- von Ahsen, N., Oellerich, M. and Schutz, E. (2001) Limitations of genotyping based on amplicon melting temperature. *Clin. Chem.* **47**, 1331–1332
- Gundry, C., Vandersteen, J., Reed, G., Pryor, R., Chen, J. and Wittwer, C. (2003) Amplicon melting analysis with labelled primers: a closed-tube method for differentiating homozygotes and heterozygotes. *Clin. Chem.* **49**, 396–406
- Wittwer, C., Reed, G., Gundry, C., Vandersteen, J. and Pryor, R. (2003) High-resolution genotyping by amplicon melting analysis using LCGreen. *Clin. Chem.* **49**, 853–860
- Liew, M., Pryor, R., Palais, R., Meadows, C., Erali, M., Lyon, E. and Wittwer, C. (2004) Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. *Clin. Chem.* **50**, 1156–1164
- Millward, H., Samowitz, W., Wittwer, C. and Bernard, P. (2002) Homogeneous amplification and mutation scanning of the p53 gene using fluorescent melting curves. *Clin. Chem.* **48**, 1321–1328
- Zhou, L., Myers, A., Vandersteen, J., Wang, L. and Wittwer, C. (2004) Closed-tube genotyping with unlabelled oligonucleotide probes and a saturating DNA dye. *Clin. Chem.* **50**, 1328–1335
- Zhou, L., Wang, L., Palais, R., Pryor, R. and Wittwer, C. (2005) High-resolution DNA melting analysis for simultaneous mutation scanning and genotyping in solution. *Clin. Chem.* **51**, 1770–1777
- Vandersteen, J., Bayrak-Toydemir, P., Palais, R. and Wittwer, C. (2007) Identifying common genetic variants by high-resolution melting. *Clin. Chem.* **53**, 1191–1198
- Herrmann, M., Durtschi, J., Bromley, L., Wittwer, C. and Voelkerding, K. (2006) Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. *Clin. Chem.* **52**, 494–503
- Herrmann, M., Durtschi, J., Wittwer, C. and Voelkerding, K. (2007) Expanded instrument comparison of amplicon DNA melting for mutation scanning and genotyping. *Clin. Chem.* **53**, 1544–1548
- Herrmann, M., Durtschi, J., Bromley, L., Wittwer, C. and Voelkerding, K. (2007) Instrument comparison for heterozygote scanning of single and double heterozygotes: a correction and extension of Herrmann et al., *Clin Chem*; **52**:494–503. *Clin. Chem.* **53**, 150–152
- Graham, R., Liew, M., Meadows, C., Lyon, E. and Wittwer, C. (2005) Distinguishing different heterozygotes by high-resolution melting. *Clin. Chem.* **51**, 1295–1298
- Seipp, M., Durtschi, J., Liew, M., Williams, J., Damjanovich, K., Pont-Kingdon, G., Lyon, E., Voelkerding, K. and Wittwer, C. (2007) Unlabeled oligonucleotides as internal temperature controls for genotyping by amplicon melting. *J. Mol. Diagn.* **9**, 284–289
- Hung, C., Lee, C., Chang, C., Jong, Y., Chen, C., Hsieh, W., Su, Y. and Lin, W. (2008) Genotyping of the G1138A mutation of the *FGFR3* gene in patients with achondroplasia using high-resolution melting analysis. *Clin. Biochem.* **41**, 162–166
- Takano, E., Mitchell, G., Fox, S. and Dobrovic, A. (2008) Rapid detection of carriers with *BRCA1* and *BRCA2* mutations using high resolution melting analysis. *BMC Cancer* **8**, 59
- Margraf, R., Mao, R., Highsmith, W., Holtegaard, L. and Wittwer, C. (2006) Mutation scanning of the *RET* protooncogene using high-resolution melting analysis. *Clin. Chem.* **52**, 138–141
- Kennerson, M., Warburton, T., Nelis, E., Brewer, M., Polly, P., De Jonghe, P., Timmerman, V. and Nicholson, G. (2007) Mutation scanning of the *GJB1* gene with high-resolution melting analysis: implications for mutation scanning of genes for Charcot-Marie-Tooth disease. *Clin. Chem.* **53**, 349–352

- 20 Laurie, A., Smith, M. and George, P. (2007) Detection of Factor VIII gene mutations by high-resolution melting analysis. *Clin. Chem.* **53**, 2211–2214
- 21 Lonie, L., Porter, D., Fraser, M., Cole, T., Wise, C., Yates, L., Wakeling, E., Blair, E., Morava, E., Monaco, A. and Ragoussis, J. (2006) Determination of the mutation spectrum of the *EXT1/EXT2* genes in British Caucasian patients with multiple osteochondromas, and exclusion of six candidate genes in EXT negative cases. *Hum. Mutat.* **27**, 1160
- 22 Krypuy, M., Ahmed, A., Etemadmoghadam, D., Hyland, S., Australian Ovarian Cancer Study Group, deFazio, A., Fox, S., Brenton, J., Bowtell, D. and Dobrovic, A. (2007) High resolution melting for mutation scanning of TP53 exons 5–8. *BMC Cancer* **7**, 168
- 23 de Leeneer, K., Coene, I., Poppe, B., de Paepe, A. and Claes, K. (2008) Rapid and sensitive detection of *BRCA1/2* mutations in a diagnostic setting: comparison of two high-resolution melting platforms. *Clin. Chem.* **54**, 982–989
- 24 Do, H., Krypuy, M., Mitchell, P., Fox, S. and Dobrovic, A. (2008) High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. *BMC Cancer* **8**, 142
- 25 Lin, S., Su, Y., Hung, C., Tsay, W., Chiou, S., Chang, C., Ho, H. and Lee, C. (2008) Mutation spectrum of 122 hemophilia A families from Taiwanese population by LD-PCR, DHPLC, multiplex PCR and evaluating the clinical application of HRM. *BMC Med. Genet.* **9**, 53
- 26 Bastien, R., Lewis, T., Hawkes, J., Quackenbush, J., Robbins, T., Palazzo, J., Perou, C. and Bernard, P. (2008) High-throughput amplicon scanning of the *TP53* gene in breast cancer using high-resolution fluorescent melting curve analysis and automatic mutation calling. *Hum. Mutat.* **29**, 757–764
- 27 Dobrowolski, S., McKinney, J., Amat di San Filippo, C., Giak Sim, K., Wilcken, B. and Longo, N. (2005) Validation of dye-binding/high-resolution thermal denaturation for the identification of mutations in the *SLC22A5* gene. *Hum. Mutat.* **25**, 306–313
- 28 Takano, T., Ohe, Y., Tsuta, K., Fukui, T., Sakamoto, H., Yoshida, T., Tateishi, U., Nokihara, H., Yamamoto, N., Sekine, I. et al. (2007) Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non-small cell lung cancer treated with Gefitinib. *Clin. Cancer Res.* **13**, 5385–5390
- 29 Nomoto, K., Tsuta, K., Takano, T., Fukui, T., Yokozawa, K., Sakamoto, H., Yoshida, T., Maeshima, A., Shibata, T., Furuta, K. et al. (2006) Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. *Am. J. Clin. Pathol.* **126**, 608–615
- 30 Sestini, R., Provenzano, A., Bacci, C., Orlando, C., Genuardi, M. and Papi, L. (2008) NF2 mutation screening by denaturing high-performance liquid chromatography and high-resolution melting analysis. *Genet. Test.* **12**, 311–318
- 31 Chou, L., Lyon, E. and Wittwer, C. (2005) A comparison of high-resolution melting analysis with denaturing high-performance liquid chromatography for mutation scanning. *Am. J. Clin. Pathol.* **124**, 330–338
- 32 Polakova, K., Lopotova, T., Klamova, H. and Moravcova, J. (2008) High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. *Leuk. Res.* **32**, 1236–1243
- 33 Liyanage, K., Hooper, A., Defesche, J., Burnett, J. and van Bockxmeer, F. (2008) High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. *Ann. Clin. Biochem.* **45**, 170–176
- 34 Willmore-Payne, C., Holden, J. and Layfield, L. (2006) Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. *Mod. Pathol.* **19**, 634–640
- 35 Dobrowolski, S., Ellingson, C., Caldovic, L. and Tuchman, M. (2007) Streamlined assessment of gene variants by high resolution melt profiling utilising the ornithine transcarbamylase gene as a model system. *Hum. Mutat.* **28**, 1133–1140
- 36 Dobrowolski, S., Ellingson, C., Coyne, T., Grey, J., Martin, R., Naylor, E., Koch, R. and Levy, H. (2007) Mutations in the phenylalanine hydroxylase gene identified in 95 patients with phenylketonuria using novel systems of mutation scanning and specific genotyping based upon thermal melt profiles. *Mol. Genet. Metab.* **91**, 218–227
- 37 McKinney, J., Longo, N., Hahn, S., Matern, D., Rinaldo, P., Strauss, A. and Dobrowolski, S. (2004) Rapid, comprehensive screening of the human medium chain acyl-CoA dehydrogenase gene. *Mol. Genet. Metab.* **82**, 112–120
- 38 Willmore-Payne, C., Holden, J. and Layfield, L. (2006) Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression and hormone receptor expression. *Hum. Pathol.* **37**, 755–763
- 39 Smith, G., Chadwick, B., Willmore-Payne, C. and Bentz, J. (2008) Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. *J. Clin. Pathol.* **61**, 487–493
- 40 Willmore, C., Holden, J., Zhou, L., Tripp, S., Wittwer, C. and Layfield, L. (2004) Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. *Am. J. Clin. Pathol.* **122**, 206–216
- 41 Audrezet, M., Dabricot, A., Le Marechal, C. and Ferec, C. (2008) Validation of high-resolution DNA melting analysis for mutation scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. *J. Mol. Diagn.* **10**, 424–434
- 42 Krypuy, M., Newnham, G., Thomas, D., Conron, D. and Dobrovic, A. (2006) High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. *BMC Cancer* **6**, 295
- 43 Gundry, C., Dobrowolski, S., Martin, Y., Robbins, T., Nay, L., Boyd, N., Coyne, T., Wall, M., Wittwer, C. and Teng, D. (2008) Base-pair neutral homozygotes can be discriminated by calibrated high-resolution melting of small amplicons. *Nucleic Acids Res.* **36**, 3401–3408
- 44 Odell, I., Cloud, J., Seipp, M. and Wittwer, C. (2005) Rapid species identification within the *Mycobacterium chelonae-abscessus* group by high-resolution melting analysis of hsp65 PCR products. *Am. J. Clin. Pathol.* **123**, 96–101
- 45 Slinger, R., Bellfroy, D., Desjardins, M. and Chan, F. (2007) High-resolution melting assay for the detection of *gyrA* mutations causing quinolone resistance in *Salmonella enterica* serovars Typhi and Paratyphi. *Diagn. Microbiol. Infect. Dis.* **57**, 455–458
- 46 Reed, G. and Wittwer, C. (2004) Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. *Clin. Chem.* **50**, 1748–1754
- 47 Zhou, L., Vandersteen, J., Wang, L., Fuller, T., Taylor, M., Palais, B. and Wittwer, C. (2004) High-resolution DNA melting curve analysis to establish HLA genotypic identity. *Tissue Antigens* **64**, 156–164
- 48 Simi, L., Pratesi, N., Vignoli, M., Sestini, R., Cianchi, F., Valanzano, R., Nobili, S., Mini, E., Pazzagli, M. and Orlando, C. (2008) High-resolution melting analysis for rapid detection of *KRAS*, *BRAF*, and *PIK3CA* gene mutations in colorectal cancer. *Am. J. Clin. Pathol.* **130**, 247–253
- 49 Montgomery, J., Wittwer, C., Palais, R. and Zhou, L. (2007) Simultaneous mutation scanning and genotyping by high-resolution DNA melting analysis. *Nat. Protocols* **2**, 59–66
- 50 Taylor, C. and Taylor, G. (2004) Current and emerging techniques for diagnostic mutation detection: an overview of methods for mutation detection. In *Molecular Diagnosis of Genetic Disease*, 2nd edn (Elles, R. and Mountford, R., eds), pp. 9–44, Humana Press, Totowa

Received 27 October 2008
doi:10.1042/BST0370433